ReviewVascular health and risk management2008
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Review in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 344 citations in OpenAlex.
- The Role of Soluble Corn Fiber on Glycemic and Insulin Response.Nutrients · 2020Trial
- Computer-aided molecular engineering of novel imidazolone-chalcone conjugates as antidiabetic agent: synthesis, molecular docking, DFT study, enzyme kinetics and ADME profiling.Journal of computer-aided molecular design · 2026Article
- Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus.BMC pharmacology & toxicology · 2026Observational
- Design, Synthesis, In Vitro, and In Silico Enzymatic Evaluations of New Chrysin Sulfonohydrazide Derivatives as Potent α‑Glucosidase Inhibitors.ACS omega · 2026Article
- Chemical Composition and Biological Activities of Propolis From Eastern Anatolia: Antioxidant, Enzyme Inhibitory, and Antimicrobial Activities.Chemistry & biodiversity · 2026Article
- Characterizing the Antihyperglycemic Activity and Underlying Mechanisms of the Aqueous Extract of the Leaves fromMolecules (Basel, Switzerland) · 2026Article
- Red Macroalgae as Sources of Antioxidant and Multifunctional Ingredients for Functional Foods: A Biorefinery Approach.Marine drugs · 2026Article
- Exploring the synthesis of conduritol derivatives: strategies, challenges, and advances.RSC advances · 2026Review
- Black Oat (Current pharmaceutical design · 2026Article
- Discovery of α-glucosidase inhibitors from Paenibacillus sp. JNUCC 31 via genome mining, fatty acid profiling, and in silico analysis.Scientific reports · 2025Article
- Computational Evaluation of Azinane-Amide-Coupled Triazoles Enabled by an Alkali Metal Reagent as Anti-Enzymatic Agents.ACS omega · 2025Article
- Exploring antioxidant properties and antidiabetic potential of ten underutilized Sri Lankan fruits.BMC complementary medicine and therapies · 2025Article
- Polyphenolic Profiling and Evaluation of Antioxidant, Antidiabetic, Anti-Alzheimer, and Antiglaucoma Activities ofLife (Basel, Switzerland) · 2025Article
- Synthesis, structural insights and bio-evaluation ofRSC advances · 2025Article
- Lannea edulis lowers blood glucose by modulating absorption, utilization, and pancreatic function in diabetic rats.Frontiers in pharmacology · 2025Article
- Natural solutions for diabetes: the therapeutic potential of plants and mushrooms.Frontiers in nutrition · 2025Review
- Modern Approaches to Diabetes: The Role of Phytochemicals in Targeting Molecular Receptors.Current topics in medicinal chemistry · 2025Review
- Exploring the antidiabetic activity of potential probiotic bacteria isolated from traditional fermented beverage.World journal of microbiology & biotechnology · 2024Article
- The Potential Therapeutic Use of Agarwood for Diabetes: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pharmacophore-based 3D-QSAR modeling, virtual screening, docking, molecular dynamics and biological evaluation studies for identification of potential inhibitors of alpha-glucosidase.Journal of molecular modeling · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.